


# 글로벌 제약사 파이프라인 분석

## - Roche -

2022. 06.


국가신약개발사업단

## • 질환별 파이프라인



질환분야	개수	비중
Oncology	77	53%
Neuroscience	20	14%
Immunology	18	13%
Infectious	12	8%
Ophthalmology	10	7%
Hematology	4	3%
Metabolic	2	1%
Genitourinary	1	1%
<b>합계</b>	<b>144개</b>	<b>100%</b>

• 물질별 파이프라인



물질	개수	비중
Antibody	74	51%
Small molecules	35	24%
N/A (Not Applicable)	9	6%
Protein	8	6%
Gene Therapy	6	4%
RNA	4	3%
Cell therapy	3	2%
Vaccine	2	1.5%
ADC	2	1.5%
Peptide	1	1%
<b>합계</b>	<b>144개</b>	<b>100%</b>

## • 상세 파이프라인

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
1	Genitourinary	Phase 1	CHU			Endometriosis	N/A	N/A	N/A	Mono	Chugai
2	Hematology	Registration	RG6013	Hemlibra	emicizumab	Mild to moderate hemophilia A, patients without FVIII inhibitors	Antibody	Factor IXa, Factor X	Bispecific antibody (Factor IXa, Factor X activator)	Mono	Chugai
3	Hematology	Phase 2	RG6357			Hemophilia A	Gene Therapy	Factor VIII	Factor VIII activator	Mono	-
4	Hematology	Phase 2	RG6358			Hemophilia A with inhibitors to factor VIII	Gene Therapy	Factor VIII	Factor VIII activator	Mono	-
5	Hematology	Phase 1	NXT007			Hemophilia A	Antibody	Factor IXa, Factor X	Bispecific antibody (Factor IXa, Factor X activator)	Mono	Chugai
6	Immunology	Phase 3	RG3648	Xolair	omalizumab	Food allergy	Antibody	IgE	IgE inhibitor	Mono	Novartis
7	Immunology	Phase 3	RG6107		crovalimab	Paroxysmal Nocturnal Hemoglobinuria C5 inhibitor naïve Patients	Antibody	C5	C5 inhibitor	Mono	Chugai
8	Immunology	Phase 3	RG6107		crovalimab	Paroxysmal Nocturnal Hemoglobinuria (PNH) patients switching from a C5 inhibitor	Antibody	C5	C5 inhibitor	Mono	Chugai
9	Immunology	Phase 3	RG6354		zincpentraxin alpha	Idiopathic Pulmonary Fibrosis	Protein	FCGR	FCGR agonist	Mono	-
10	Immunology	Phase 3	RG7159	Gazyva/ Gazyvaro	obinutuzumab	Systemic Lupus Erythematosus	Antibody	CD20	Cytotoxic to cells expressing B Lymphocyte Antigen CD20	Mono	Biogen
11	Immunology	Phase 3	RG7159	Gazyva/ Gazyvaro	obinutuzumab	Lupus nephritis	Antibody	CD20	Cytotoxic to cells expressing B Lymphocyte Antigen CD20	Mono	Biogen

No.	2질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
12	Immunology	Phase 3	RG7159-7	Gazyva/ Gazyvaro	obinutuzumab	Membranous Nephropathy	Antibody	CD20	Cytotoxic to cells expressing B Lymphocyte Antigen CD20	Mono	Biogen
13	Immunology	Phase 2	IONIS-FB-LRx			IgA-nephropathy	RNA	factor B	Antisense therapy	Mono	Ionis
14	Immunology	Phase 2	RG6149		astegolimab	Chronic obstructive disease	Antibody	IL-33	IL-33 inhibitor	Mono	Amgen
15	Immunology	Phase 2	RG6354		zinpentraxin al fa	Myelofibrosis	Protein	FCGR	FCGR agonist	Mono	-
16	Immunology	Phase 2	RG6173			Asthma	Antibody	Tryptase	Tryptase Inhibitor	Mono	-
17	Immunology	Phase 1	RG6107		crovalimab	Paroxysmal nocturnal Hemoglobinuria	Antibody	C5	C5 inhibitor	Mono	Chugai
18	Immunology	Phase 1	RG6287			Inflammatory bowel Disease	N/A	N/A	N/A	Mono	-
19	Immunology	Phase 1	RG6314			Asthma	N/A	N/A	N/A	Mono	-
20	Immunology	Phase 1	RG6315			Systemic Sclerosis	N/A	N/A	N/A	Mono	-
21	Immunology	Phase 1	RG6418		selnoflast	Inflammation	Small molecules	NLRP3	NLRP3 inhibitor	Mono	-
22	Immunology	Phase 1	RG7828		mosunetuzum ab	Systemic Lupus Erythematosus	Antibody	CD20/CD3	Bispecific antibody (CD20, CD3 agonist)	Mono	-
23	Immunology	Phase 1	RG7880		efmarodocoki n alfa	Acute graft-versus-host disease	Protein	IL22-Fc, FCGR2	IL22-Fc, FCGR2 agonist	Mono	-
24	Infectious	Registration	RG6152	Xofluza	baloxavir marboxil	Influenza, pediatric patients (1-12yr)	Small molecules	Cap-dependent endonuclease	cap-dependent endonuclease inhibitor	Mono	Shionogi
25	Infectious	Registration	RG6412	REGEN-COV -2	imdevimab	Hospitalised adult patients with COVID-19	Antibody	SARS-CoV-2 S	SARS-CoV-2 S inhibitor	Mono	Regeneron

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
26	Infectious	Registration	RG6413	REGEN-COV-2	casirivimab	Hospitalized patients with COVID-19	Antibody	SARS-CoV-2 S	SARS-CoV-2 S inhibitor	Mono	Regeneron
27	Infectious	Phase 3	RG6152	Xofluza	baloxavir marboxil	Influenza, pediatric patients (0-1yr)	Small molecules	Cap-dependent Endonuclease	cap-dependent endonuclease inhibitor	Mono	Shionogi
28	Infectious	Phase 3	RG6152	Xofluza	baloxavir marboxil	Influenza, direct transmission	Small molecules	Cap-dependent endonuclease	cap-dependent endonuclease inhibitor	Mono	Shionogi
29	Infectious	Phase 2	RG6084			Chronic hepatitis B Infection	N/A	PD-L1/PD-1	PD-L1/PD-1 inhibitor	Mono	-
30	Infectious	Phase 2	RG6346			Hepatitis B virus	RNA	Hepatitis B Virus Surface Antigen	Antisense therapy	Mono	novo nordisk
31	Infectious	Phase 2	RG7854			Chronic hepatitis B Infection	Small molecules	TLR7	TLR7 agonist	Mono	-
32	Infectious	Phase 1	RG6006			Acinetobacter baumannii infections	Small molecules	N/A	N/A	Mono	-
33	Infectious	Phase 1	RG6319			Complicated urinary track infection	Small molecules	LepB	LepB inhibitor	Mono	-
34	Infectious	Phase 1	RG7854			Chronic hepatitis B Infection	Small molecules	TLR7	TLR7 agonist	Mono	-
35	Infectious	Phase 1	RG7907			Chronic hepatitis B Infection	Small molecules	HBV Capsid Protein	Capsid Protein inhibitor	Mono	-
36	Metabolic	Phase 2	RG6359			Pompe disease	Gene Therapy	Lysosomal Alpha Glucosidase	Lysosomal Alpha Glucosidase activator	Mono	-
37	Metabolic	Phase 1	RG6338			Metabolic diseases	Small molecules	N/A	N/A	Mono	-
38	Neuroscience	Registration	RG7916	Evrysdi	risdiplam	Spinal Muscular Atrophy pediatric <2 months	Small molecules	SMN2	SMN2 splicing modifier	Mono	PTC Therapeutics

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
39	Neuroscience	Phase 3	RG1450		gantenerumab	Alzheimer's disease	Antibody	beta amyloid	beta amyloid inhibitor	Mono	Morphosys
40	Neuroscience	Phase 3	RG6042		tominersen	Huntington's disease	RNA	HTT protein	Antisense therapy	Mono	Ionis
41	Neuroscience	Phase 3	RG6168	Enspryng	satralizumab	Myasthenia Gravis	Antibody	IL-6	IL-6 Antagonist	Mono	Chugai
42	Neuroscience	Phase 3	RG6356		delandistrogene moxeparvec (SRP-9001)	Duchenne muscular dystrophy	Gene Therapy	Dystrophin (DMD)	Dystrophin (DMD) Activator	Mono	-
43	Neuroscience	Phase 3	RG7845		fenebrutinib	Primary Progressive Multiple Sclerosis	Small molecules	BTK	BTK inhibitor	Mono	-
44	Neuroscience	Phase 3	RG7845		fenebrutinib	Relapsing Multiple Sclerosis	Small molecules	BTK	BTK inhibitor	Mono	-
45	Neuroscience	Phase 2	RG6100		semorinemab	Alzheimer's disease	Antibody	tau	tau inhibitor	Mono	AC Immune
46	Neuroscience	Phase 2	RG6102		Brain shuttle gantenerumab	Alzheimer's disease	Antibody	beta amyloid	beta amyloid inhibitor	Mono	-
47	Neuroscience	Phase 2	RG7412		crenezumab	Alzheimer's disease	Antibody	beta amyloid	beta amyloid inhibitor	Mono	-
48	Neuroscience	Phase 2	RG7816		alogabat	Autism spectrum disorder	Small molecules	GABA A receptor	GABA A receptor modulator	Mono	-
49	Neuroscience	Phase 2	RG7906		ralmitaront	Psychiatric disorders	Small molecules	TAAR1	TAAR1 receptor agonist	Mono	-
50	Neuroscience	Phase 2	RG7935		prasinezumab	Parkinson's disease	Antibody	alpha-synuclein	alpha-synuclein inhibitor	Mono	Prothena
51	Neuroscience	Phase 1	RG6035			Multiple Sclerosis	Antibody	CD20	CD20 inhibitor	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
52	Neuroscience	Phase 1	RG6091		rugonersen	Angelman syndrome	Gene Therapy	Ubiquitin protein ligase E3A	Ubiquitin protein ligase E3A activator	Mono	-
53	Neuroscience	Phase 1	RG6163			Psychiatric disorders	Small molecules	N/A	N/A	Mono	-
54	Neuroscience	Phase 1	RG6182			Neurodegenerative diseases	Gene Therapy	new molecular entity	N/A	Mono	-
55	Neuroscience	Phase 1	RG6237			Neuromuscular disorders	Antibody	MSTN	MSTN inhibitor	Mono	-
56	Neuroscience	Phase 1	RG6289			Alzheimer's disease	N/A	N/A	N/A	Mono	-
57	Neuroscience	Phase 1	RG7637			Neurodevelopmental disorders	N/A	new molecular entity	N/A	Mono	-
58	Oncology	Registration	RG6026		glofitamab	3L+ Diffuse Large B-Cell Lymphoma	Antibody	CD20/CD3	Bispecific antibody (CD20, CD3 agonist)	Mono	-
59	Oncology	Registration	RG7446	Tecentriq	atezolizumab	Neoadjuvant TNBC	Antibody	PDL1	anti-PDL1	Mono	-
60	Oncology	Registration	RG7596	Polivy	polatuzumab vedotin	1L diffuse large B-cell lymphoma	Antibody	CD79b	ADC consists of a monoclonal antibody anti-CD79b	Mono	Seagen
61	Oncology	Registration	RG7828		mosunetuzumab	3L+ Follicular Lymphoma	Antibody	CD20/CD3	Bispecific antibody (CD20, CD3 agonist)	Mono	-
62	Oncology	Phase 3	RG3502	Kadcyla	trastuzumab emtansine	2L+ HER-2 positive PD-L1 positive mBC in combination with Tecentriq	ADC	HER2, EGFR2, ErbB2	Cytotoxic to cells expressing B Lymphocyte Antigen HER2, EGFR2, ErbB2	Combination	ImmunoGen
63	Oncology	Phase 3	RG3502-10	Kadcyla	trastuzumab emtansine	High risk patients with adjuvant HER2-positive breast cancer in combination with Tecentriq	ADC	HER2, EGFR2, ErbB2	Cytotoxic to cells expressing B Lymphocyte Antigen HER2, EGFR2, ErbB2	Combination	-



No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
64	Oncology	Phase 3	RG6026		glofitamab	2L+ SCT-ineligible Diffuse Large B-Cell Lymphoma	Antibody	CD20/CD3	Bispecific antibody (CD20, CD3 agonist)	Mono	-
65	Oncology	Phase 3	RG6058		tiragolumab	1L NSCLC in combination with Tecentriq	Antibody	TIGIT	TIGIT antagonist	Combination	-
66	Oncology	Phase 3	RG6058		tiragolumab	Stage III unresectable 1L NSCLC in combination with Tecentriq	Antibody	TIGIT	TIGIT antagonist	Combination	-
67	Oncology	Phase 3	RG6058		tiragolumab	Locally advanced esophageal cancer	Antibody	TIGIT	TIGIT antagonist	Mono	-
68	Oncology	Phase 3	RG6107		crovalimab	Atypical Hemolytic Uremic Syndrome	Antibody	C5	C5 inhibitor	Mono	Chugai
69	Oncology	Phase 3	RG6114		inavolisib	Metastatic ER-positive and HER2-negative breast cancer	Small molecules	PI3 kinase (PI3K)	PI3 kinase (PI3K) inhibitor	Mono	-
70	Oncology	Phase 3	RG6171		giredestrant	Adjuvant ER+ breast cancer	Small molecules	estrogen receptor	SERD(selective estrogen receptor degrader)	Mono	-
71	Oncology	Phase 3	RG7440		ipatasertib	1L castration-resistant prostate cancer	Small molecules	protein kinase B (AKT, AKT2, AKT3)	pan-AKT inhibitor	Mono	Array BioPharma
72	Oncology	Phase 3	RG7446	Tecentriq	atezolizumab	Adjuvant renal cell carcinoma	Antibody	PDL1	anti-PDL1	Mono	-
73	Oncology	Phase 3	RG7446	Tecentriq	atezolizumab	Adjuvant hepatocellular carcinoma in combination with Avastin	Antibody	PDL1	anti-PDL1	Combination	-
74	Oncology	Phase 3	RG7446	Tecentriq	atezolizumab	NSCLC subcutaneous formulation	Antibody	PDL1	anti-PDL1	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
75	Oncology	Phase 3	RG7446	Tecentriq	atezolizumab	2L NSCLC treatment in combination with cabozantinib	Antibody	PDL1	anti-PDL1	Combination	-
76	Oncology	Phase 3	RG7446	Tecentriq	atezolizumab	Advanced renal cell carcinoma after immune checkpoint inhibitor treatment in combination with cabozantinib	Antibody	PDL1	anti-PDL1	Combination	-
77	Oncology	Phase 3	RG7446	Tecentriq	atezolizumab	1L metastatic urothelial carcinoma	Antibody	PDL1	anti-PDL1	Mono	-
78	Oncology	Phase 3	RG7446	Tecentriq	atezolizumab	1L extensive stage-small cell lung cancer, maintenance	Antibody	PDL1	anti-PDL1	Mono	-
79	Oncology	Phase 3	RG7446	Tecentriq	atezolizumab	Adjuvant TNBC in combination with paclitaxel	Antibody	PDL1	anti-PDL1	Combination	-
80	Oncology	Phase 3	RG7446	Tecentriq	atezolizumab	1L metastatic TNBC in combination with capecitabine or carboplatin/gemcitabine	Antibody	PDL1	anti-PDL1	Combination	-
81	Oncology	Phase 3	RG7446	Tecentriq	atezolizumab	adjuvant squamous cell carcinoma of the head and neck	Antibody	PDL1	anti-PDL1	Mono	-
82	Oncology	Phase 3	RG7446	Tecentriq	atezolizumab	ctDNA+ high risk muscle-invasive bladder cancer	Antibody	PDL1	anti-PDL1	Mono	-
83	Oncology	Phase 3	RG7601	Venclexta/ Venclyxto	venetoclax	Relapsed/refractory t(11;14)-positive multiple myeloma	Small molecules	BCL-2	BCL-2 selective inhibitor	Mono	AbbVie

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
84	Oncology	Phase 3	RG7601	Venclexta/ Venclyxto	venetoclax	Newly diagnosed higher-risk myelodysplastic syndrome	Small molecules	BCL-2	BCL-2 selective inhibitor	Mono	AbbVie
85	Oncology	Phase 3	RG7828		mosunetuzumab	2L+ Follicular Lymphoma	Antibody	CD20/CD3	Bispecific antibody (CD20, CD3 agonist)	Mono	-
86	Oncology	Phase 3	RG7853	Alecensa	alectinib	Adjuvant ALK-positive NSCLC	Small molecules	ALK (anaplastic lymphoma kinase)	ALK inhibitor	Mono	Chugai
87	Oncology	Phase 2	RG6026		glofitamab	1L ctDNA higher risk Diffuse Large B-Cell Lymphoma	Antibody	CD20/CD3	Bispecific antibody (CD20, CD3 agonist)	Mono	-
88	Oncology	Phase 2	RG6058		tiragolumab	1L recurrent/metastatic PD-L1 positive squamous cell head and neck carcinoma	Antibody	TIGIT	TIGIT antagonist	Mono	-
89	Oncology	Phase 2	RG6058		tiragolumab	Cervical cancer in combination with Tecentriq	Antibody	TIGIT	TIGIT antagonist	Combination	-
90	Oncology	Phase 2	RG6058		tiragolumab	1L non-squamous NSCLC in combination with Tecentriq	Antibody	TIGIT	TIGIT antagonist	Combination	-
91	Oncology	Phase 2	RG6058		tiragolumab	Neoadjuvant and adjuvant non-squamous NSCLC in combination with Tecentriq	Antibody	TIGIT	TIGIT antagonist	Combination	-
92	Oncology	Phase 2	RG6107		crovalimab	Sickle cell disease	Antibody	C5	C5 inhibitor	Mono	Chugai
93	Oncology	Phase 2	RG6139			Solid tumors	Antibody	PD1, LAG3	Bispecific antibody(PD1, LAG3)	Mono	-
94	Oncology	Phase 2	RG6171		giredestrant	Neoadjuvant ER+ breast cancer	Small molecules	estrogen receptor	SERD(selective estrogen receptor degrader)	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
95	Oncology	Phase 2	RG6171		giredestrant	ER-positive and HER2-negative 2/3L metastatic breast cancer	Small molecules	estrogen receptor	SERD(selective estrogen receptor degrader)	Mono	-
96	Oncology	Phase 2	RG6180		autogene cevumeran	1L melanoma	Vaccine	N/A	Cancer vaccine	Mono	BioNTech
97	Oncology	Phase 2	RG6416		bepranemab	Alzheimer's disease	Antibody	tau	tau inhibitor	Mono	UCB
98	Oncology	Phase 2	RG7601	Venclexta/ Venclyxto	venetoclax	Relapsed/refractory Multiple Myeloma	Small molecules	BCL-2	BCL-2 selective inhibitor	Mono	AbbVie
99	Oncology	Phase 1	CD137 agonist switch antibody			Solid tumors	Antibody	N/A	CD137 agonist	Mono	Chugai
100	Oncology	Phase 1	LUNA18			Solid tumors	Peptide	RAS	RAS inhibitor	Mono	Chugai
101	Oncology	Phase 1	RG6007			Adult acute Myeloid Leukemia	Antibody	WT1, CD3	Bispecific antibody (WT1, CD3 agonist)	Mono	-
102	Oncology	Phase 1	RG6026		glofitamab	Relapsed/refractory non-Hodgkin's lymphoma	Antibody	CD20 CD3	Bispecific antibody (CD20, CD3 agonist)	Mono	-
103	Oncology	Phase 1	RG6058		tiragolumab	Hematologic and solid tumors	Antibody	TIGIT	TIGIT antagonist	Combination	-
104	Oncology	Phase 1	RG6076			Hematological tumors	Protein	4-1BB, CD19	4-1BB, CD19 agonist	Mono	-
105	Oncology	Phase 1	RG6129			Solid tumors	Antibody	HLA-A2, CD3	Bispecific antibody (HLA-A2, CD3 agonist)	Mono	-
106	Oncology	Phase 1	RG6156			Glioblastoma	Antibody	EGFR, CD3	Bispecific antibody (EGFR, CD3 agonist)	Mono	-
107	Oncology	Phase 1	RG6160		cevostamab	Relapsed/refractory Multiple Myeloma	Antibody	FcRH5, CD3	Bispecific antibody (FcRH5, CD3 agonist)	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
108	Oncology	Phase 1	RG6171		giredestrant	ER-positive and HER2- metastatic breast cancer	Small molecules	estrogen receptor	SERD(selective estrogen receptor degrader)	Mono	-
109	Oncology	Phase 1	RG6180		autogene cevumeran	Solid tumors	Vaccine	N/A	Cancer vaccine	Mono	BioNTech
110	Oncology	Phase 1	RG6185		belvarafenib	Solid tumors	Small molecules	MAP kinase	MAP kinase inhibitor	Mono	Hamni
111	Oncology	Phase 1	RG6189			Solid tumors	Antibody	CD40, FAP	Bispecific antibody (CD40, FAP agonist)	Mono	-
112	Oncology	Phase 1	RG6194		runimotamab	Metastatic HER2 positive cancers	Antibody	HER2, CD3	Bispecific antibody (HER2, CD3 agonist)	Mono	-
113	Oncology	Phase 1	RG6234			Multiple Myeloma	Antibody	GPRC5D	Anti-GPRC5D T-cell engager	Mono	-
114	Oncology	Phase 1	RG6279			Solid tumors	Protein	PD1, IL2v	PD1, IL2v antagonist	Mono	-
115	Oncology	Phase 1	RG6286			Locally advanced or metastatic colorectal cancer	Small molecules	N/A	N/A	Mono	-
116	Oncology	Phase 1	RG6290			Solid tumors	Protein	MAGEA4, CD3	Bispecific antibody (MAGEA4, CD3 agonist)	Mono	Immunocore
117	Oncology	Phase 1	RG6292			Solid tumors	Antibody	IL-2 receptor alpha chain(CD25)	Cytotoxic to cells expressing IL-2 receptor alpha chain(CD25)	Mono	-
118	Oncology	Phase 1	RG6323			Solid tumors	Protein	IL-15 receptor alpha chain, IL-15	IL-15 inhibitor	Mono& Combination	-
119	Oncology	Phase 1	RG6330			Metastatic solid tumors with KRAS G12C mutation	Small molecules	KRAS G12C	KRAS G12C inhibitor	Mono	-
120	Oncology	Phase 1	RG6333			Relapsed/refractory non-Hodgkin's lymphoma	Antibody	CD19, CD28	Bispecific antibody (CD19, CD28)	Combination	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
121	Oncology	Phase 1	RG6344			Solid tumors	Antibody	BRAF	BRAF inhibitor	Mono	-
122	Oncology	Phase 1	RG6392			Cancers	N/A	N/A	N/A	Mono	-
123	Oncology	Phase 1	RG6433			Solid tumors	Small molecules	SHP2	SHP2 inhibitor	Mono	-
124	Oncology	Phase 1	RG6440			Solid tumors	Antibody	TGFB1	TGFB1 inhibitor	Mono	-
125	Oncology	Phase 1	RG7440		ipatasertib	Prostate cancer previously treated with androgen receptor-targeted therapy	Small molecules	protein kinase B (AKT, AKT2, AKT3)	pan-AKT inhibitor	Mono	-
126	Oncology	Phase 1	RG7440		ipatasertib	Metastatic castration-resistant prostate cancer and solid tumors in combination with rucaparib	Small molecules	protein kinase B (AKT, AKT2, AKT3)	pan-AKT inhibitor	Mono	-
127	Oncology	Phase 1	RG7446	Tecentriq	atezolizumab	Solid tumors (MORPHEUS platform)	Antibody	PDL1	anti-PDL1	Mono	-
128	Oncology	Phase 1	RG7601	Venclexta/ Venclyxto	venetoclax	Relapsed/refractory myelodysplastic syndromes in combination with azacitidine	Small molecules	BCL-2	BCL-2 selective inhibitor	Mono	AbbVie
129	Oncology	Phase 1	RG7686		codrituzumab	Hepatocellular carcinoma	Antibody	Glypican3	Cytotoxic to cells expressing Glypican 3	Mono	Chugai
131	Oncology	Phase 1	RG7802		cibisatamab	Solid tumors	Antibody	CEA, CD3	Bispecific antibody (CEA, CD3 agonist)	Mono	-
131	Oncology	Phase 1	RG7827			Solid tumors	Protein	FAP, 4-1BBL	Cytotoxic to cells expressing FAP, 4-1BBL 9 agonist	Mono	-
132	Oncology	Phase 1	RG7828		mosunetuzumab	Hematologic tumors	Antibody	CD20/CD3	Bispecific antibody (CD20, CD3 agonist)	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
133	Oncology	Phase 1	SPYK04			Solid tumors	Small molecules	N/A	N/A	Mono	Chugai
134	Oncology	Phase 1	SQZ-PBMC-HPV			Solid tumors	Cell therapy	Human Papillomavirus Protein E6 (E6); Human Papillomavirus Protein E7 (E7)	Cancer vaccine	Mono&Combination	-
135	Ophthalmology	Phase 3	RG7716	Vabysmo	faricimab	Macular edema secondary to central retinal vein occlusion	Antibody	VEGF/ANG2	Bispecific antibody (VEGF, ANG2)	Mono	-
136	Ophthalmology	Phase 3	RG7716	Vabysmo	faricimab	Macular edema secondary to branch retinal vein occlusion	Antibody	VEGF/ANG2	Bispecific antibody (VEGF, ANG2)	Mono	-
137	Ophthalmology	Phase 2	IONIS-FB-LRx			Geographic atrophy	RNA	factor B	Antisense therapy	Mono	Ionis
138	Ophthalmology	Phase 2	RG6147		galegenimab	Geographic atrophy	Antibody	HTRA1	HTRA1 inhibitor	Mono	-
139	Ophthalmology	Phase 2	RG6179			Diabetic macular edema	Antibody	IL-6	IL-6 inhibitor	Mono	-
140	Ophthalmology	Phase 2	RG7774			Retinal disease	Small molecules	Hepatitis B Virus Surface Antigen	Hepatitis B Virus Surface Antigen inhibitor	Mono	-
141	Ophthalmology	Phase 1	RG6120			Neovascular age-related macular degeneration	Antibody	VEGF/ ANG2	Bispecific antibody (VEGF, ANG2)	Mono	-
142	Ophthalmology	Phase 1	RG6312			Geographic atrophy	Cell therapy	N/A	N/A	Mono	Lineage Cell Therapeutics
143	Ophthalmology	Phase 1	RG6501		OpRegen	Geographic atrophy	Cell therapy	N/A	N/A	Mono	-
144	Ophthalmology	Phase 1	RG7921			Neovascular age related macular degeneration	N/A	N/A	N/A	Mono	-

자료: Roche 홈페이지, BioCentury, GlobalData